Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Assets (2016 - 2025)

Historic Assets for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $108.4 million.

  • Karyopharm Therapeutics' Assets fell 3406.07% to $108.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $108.4 million, marking a year-over-year decrease of 3406.07%. This contributed to the annual value of $108.4 million for FY2025, which is 3406.07% down from last year.
  • Latest data reveals that Karyopharm Therapeutics reported Assets of $108.4 million as of Q4 2025, which was down 3406.07% from $96.2 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Assets ranged from a high of $358.2 million in Q4 2022 and a low of $96.2 million during Q3 2025
  • Over the past 5 years, Karyopharm Therapeutics' median Assets value was $247.3 million (recorded in 2021), while the average stood at $230.2 million.
  • Its Assets has fluctuated over the past 5 years, first soared by 1731.61% in 2022, then tumbled by 5098.59% in 2025.
  • Karyopharm Therapeutics' Assets (Quarter) stood at $305.3 million in 2021, then grew by 17.32% to $358.2 million in 2022, then tumbled by 32.87% to $240.4 million in 2023, then tumbled by 31.62% to $164.4 million in 2024, then tumbled by 34.06% to $108.4 million in 2025.
  • Its last three reported values are $108.4 million in Q4 2025, $96.2 million for Q3 2025, and $104.9 million during Q2 2025.